Telix Pharmaceuticals TLX
NASDAQ TLX
$9.26 +0.23 (+2.55%)
At close: Oct 28, 2026 · 4:00 PM EDT

Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2026)

Updated

Telix Pharmaceuticals (TLX) posted Current Deferred Revenue of $390,000 for the quarter ended Jun 30, 2026.

Analysis

Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2026) Analysis & Trends

As of Dec 31, 2025, Telix Pharmaceuticals' Current Deferred Revenue came in at $402,000, down 94.2% from the prior year.

  • In prior years, Telix Pharmaceuticals' Current Deferred Revenue was $6.97 million in the year ended Dec 31, 2024 (-7.4%) and $7.52 million in the year ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,213.59 Bn 1,182.17 Bn 19.71 Bn
2 Johnson & Johnson 652.89 Bn 572.75 Bn 17.30 Bn
3 AbbVie 506.16 Bn 479.31 Bn 12.70 Bn
4 Merck 347.97 Bn 302.40 Bn 12.21 Bn
5 Novartis Ag 297.84 Bn 271.42 Bn -
6 Astrazeneca 262.79 Bn 236.55 Bn 12.86 Bn
7 Amgen 244.26 Bn 199.66 Bn 7.24 Bn
8 Gilead Sciences 197.57 Bn 171.68 Bn 6.22 Bn
9 Pfizer 168.03 Bn 114.97 Bn 10.94 Bn
10 Telix Pharmaceuticals 3.14 Bn 2.10 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 390,000.00
Dec 31, 2025 402,000.00
Dec 31, 2024 7.00 Mn
Dec 31, 2023 7.51 Mn
API Access

Telix Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=TLX&period=max&api_key=YOUR_API_KEY